Over Active Bladder Instillation Study - Botox

This study has been completed.
Sponsor:
Information provided by:
Mayo Clinic
ClinicalTrials.gov Identifier:
NCT00667095
First received: April 23, 2008
Last updated: May 29, 2012
Last verified: May 2012
  Purpose

The purpose of this study is to determine whether women with overactive bladder (OAB) who receive direct instillation via a catheter of a Botulinum-A Toxin (Botox) with Dimethyl Sulfoxide (DMSO) solution experience significantly better improvement of their OAB symptoms when compared to a similar group of women with OAB who receive instillation of DMSO only.


Condition Intervention Phase
Overactive Bladder
Urinary Urge Incontinence
Urinary Incontinence
Detrusor Hyperreflexia
Urge Incontinence
Procedure: Botox Instillation
Procedure: Placebo Instillation
Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Crossover Assignment
Masking: Double Blind (Subject, Investigator)
Primary Purpose: Treatment
Official Title: Evaluation of the Efficacy of Botulinum-A Toxin/DMSO Instillation in the Treatment of Women With Over Active Bladder (OAB) Syndrome and/or Urinary Urge Incontinence

Resource links provided by NLM:


Further study details as provided by Mayo Clinic:

Primary Outcome Measures:
  • To evaluate the efficacy of Botox/DMSO instillations compared to DMSO instillations alone for the treatment of OAB by assessing changes in incontinence quality of life scores [ Time Frame: 3 month follow-up ] [ Designated as safety issue: Yes ]

Secondary Outcome Measures:
  • To compare Botox/DMSO instillation and DMSO instillation by validated urinary incontinence quality of life questionnaires and measurement tools used for summarizing the frequency and severity of urinary incontinence. [ Time Frame: 1 and 3 month follow-up ] [ Designated as safety issue: Yes ]

Enrollment: 100
Study Start Date: April 2008
Study Completion Date: January 2012
Primary Completion Date: January 2012 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: 1
Botulinum-A Toxin (Botox)/Dimethyl Sulfoxide (DMSO) Solution
Procedure: Botox Instillation
Botox/DMSO
Other Names:
  • Botulinum-A Toxin
  • Botox
Placebo Comparator: 2
Dimethyl Sulfoxide (DMSO) solution
Procedure: Placebo Instillation
DMSO
Other Names:
  • Dimethyl Sulfoxide
  • DMSO

Detailed Description:

The primary objective of this study is to evaluate the efficacy of catheter-based instillation of a solution of Botox/DMSO as a novel method for treating women with overactive bladder (OAB) and secondary urinary incontinence who have failed oral pharmacologic therapy. This study will test the broad hypothesis that administration of Botox/DMSO instillations into the bladder with a urethral catheter can significantly improve symptoms and quality of life in patients with OAB when compared to DMSO installations alone. Explicitly, we hypothesize that scores on the validated Incontinence Quality of Life (I-QOL) questionnaire of women with OAB who receive Botox/DMSO instillation will be much improved at three-month follow-up compared to similar women receiving DMSO instillation alone. Our long-term goal is to offer women with detrusor hyperreflexia or OAB a less invasive alternative to surgery and an alternative to anticholenergic by mouth medications. In support of this effort, we are proposing a randomized, double-blind, placebo controlled clinical trial to be conducted in the Department of Urology at Mayo Clinic Jacksonville.

This study will have 2 groups assigned: initial and re-treat. The initial group will be randomized (as a flip of a coin) to either Botox/DMSO or DMSO instillation and will be followed for 3 months. Patients who received DMSO only instillation during the initial group will be entered into the re-treat group to receive Botox/DMSO instillation and will be followed for 3 months also. Patients who received Botox/DMSO instillation in the initial group will not be entered in the re-treat group - they will be complete from study.

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Female
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Female patient aged 18 years or older
  • No evidence of stress urinary incontinence on physical examination or urodynamics
  • Patients who have failed prior drug therapy for overactive bladder or detrusor hyperreflexia
  • Patients with symptoms and signs of OAB, detrusor hyperreflexia, urinary urgency, urinary urge incontinence.
  • Patient who is mentally competent with the ability to understand and comply with the requirements of the study
  • Patient who agrees to be available for the follow-up evaluations as required by the protocol
  • Patient who has given signed informed consent

Exclusion Criteria:

  • Patient with Post-Void Residual Urine (PVRU) greater than 100 ml on repeated measures. (Patient with a single PVRU of >100 ml and followed by two consecutive PVRU measurements of <100 ml may be included in the study)
  • Patient with greater than vesicoureteral reflux grade 1, interstitial cystitis, genitourinary fistulae
  • Patient with pelvic organ prolapse stage III or IV, i.e. the most distal part of the prolapse protruding more than 1 cm beyond the hymen (>+1), at straining
  • Patient with un-investigated hematuria
  • Patient with lower tract genitourinary malignancies
  • Patient on current medication for stress urinary incontinence, such as alpha-adrenergic agonists or duloxetine, within three weeks prior to completing the baseline Bladder Diary (estrogen therapy on a stable dose for at least two months prior to study start is allowed)
  • Patient with ongoing complications of prior anti-incontinence surgery
  • Patient who is pregnant, lactating, or planning to become pregnant within the study period
  • Patient who has received pelvic radiation
  • Patient with any condition, which could lead to significant postoperative complications, including current infection and uncontrolled diabetes.
  • Patient who is morbidly obese (defined as BMI > 40 Kg/m2)
  • Patient who is bedridden, institutionalized or in such physical condition that she cannot move to the closest bathroom without assistance from another person
  • Patient with current or acute urinary tract infection, including cystitis or urethritis. (Patient with such infections should be treated with antibiotics, with subsequent urinalysis tests confirming the absence of such infection before study inclusion)
  • Patient with any condition that would preclude treatment due to contraindications and/or warnings in the study product's labeling
  • Patient on immunomodulatory therapy (suppressive or stimulatory)
  • Patient with known lidocaine hypersensitivity or hypersensitivity to any anesthetics to be used during the treatment session/surgical procedure
  • Patient with a concurrent use of another study product within two weeks prior to study start, or who concurrently participate in any other clinical study
  • Any disease that in the opinion of the Investigator would make the patient unsuitable for the study
  • Patient with a life expectancy of less than 12 months
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00667095

Locations
United States, Florida
Mayo Clinic
Jacksonville, Florida, United States, 32224
Sponsors and Collaborators
Mayo Clinic
Investigators
Principal Investigator: Steven P Petrou, MD Mayo Clinic
  More Information

Additional Information:
No publications provided

Responsible Party: Steven P. Petrou, MD, Mayo Clinic
ClinicalTrials.gov Identifier: NCT00667095     History of Changes
Other Study ID Numbers: 07-007399
Study First Received: April 23, 2008
Last Updated: May 29, 2012
Health Authority: United States: Institutional Review Board

Keywords provided by Mayo Clinic:
OAB
Over Active Bladder
overactive bladder
Urinary Urge Incontinence
Urinary Incontinence
Botox
DMSO
bladder instillation
instillation
detrusor hyperreflexia
urge incontinence

Additional relevant MeSH terms:
Urinary Incontinence
Urinary Incontinence, Urge
Reflex, Abnormal
Urinary Bladder, Overactive
Urination Disorders
Urologic Diseases
Urological Manifestations
Signs and Symptoms
Neurologic Manifestations
Nervous System Diseases
Urinary Bladder Diseases
Botulinum Toxins, Type A
Dimethyl Sulfoxide
Neuromuscular Agents
Peripheral Nervous System Agents
Physiological Effects of Drugs
Pharmacologic Actions
Free Radical Scavengers
Antioxidants
Molecular Mechanisms of Pharmacological Action
Cryoprotective Agents
Protective Agents

ClinicalTrials.gov processed this record on April 15, 2014